GlassScriptPhysician profile
Vimal T George
NPI 1245285345
$5,166.03
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,341 · 2020: $50.13 · 2022: $256 · 2023: $275 · 2024: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,206.36 | 2019 | |
| Novo Nordisk INC | $287.15 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $149.85 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $97.09 | 2019-2024 | Shingrix, Arexvy |
| Lilly USA, LLC | $73.94 | 2023-2024 | Zepbound, Mounjaro |
| Dynavax Technologies Corporation | $71.20 | 2020-2024 | Heplisav-B |
| Otsuka America Pharmaceutical, INC. | $69.20 | 2022-2023 | Rexulti |
| Vertiflex, INC. | $46.11 | 2019 | |
| Pfizer INC. | $43.39 | 2022 | |
| Astellas Pharma US INC | $32.33 | 2023 | Veozah |
| Astrazeneca Pharmaceuticals LP | $29.10 | 2022 | |
| Dermira, INC. | $28.13 | 2019 | |
| Merck Sharp & Dohme LLC | $19.25 | 2019 | |
| Abbott Laboratories | $12.93 | 2023 | Freestyle Libre 2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vimal George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.